Skip to main content

Table 3 Clinical and genotypic characteristics between non-SHF group and SHF group

From: Effects of GRK5 and ADRB1 polymorphisms influence on systolic heart failure

Characteristic

Non-SHF group (n = 1976)

SHF group (n = 260)

P value

Age, yrs

57.05 ± 9.77

71.06 ± 11.88

0.000

Male, %

634 (32.3)

154 (59.2)

0.000

Weight, kg

62.48 ± 10.39

65.22 ± 14.03

0.006

Height, cm

160.81 ± 7.67

164.66 ± 8.98

0.000

Smoking, %

413 (21.1)

87 (33.5)

0.000

Drinking, %

268 (13.7)

44 (16.9)

0.156

Systolic BP, mmHg

133.87 ± 22.07

131.57 ± 23.17

0.124

Diastolic BP, mmHg

75.76 ± 11.77

76.27 ± 12.08

0.522

Heart rate, beats/min

73.56 ± 11.16

79.17 ± 9.83

0.000

Echocardiography

   

 LAD, mm

34.19 ± 4.86

46.72 ± 9.40

0.000

 LVESD, mm

28.95 ± 4.18

43.60 ± 13.20

0.000

 LVEDD, mm

46.66 ± 4.28

56.71 ± 12.41

0.000

 LVEF, %

65.00 ± 3.08

39.15 ± 7.79

0.000

GRK5

  

0.817

 Gln41Gln, n (%)

1380 (98.4)

221 (98.2)

 

 Gln41Leu, n (%)

22 (1.6)

4 (1.8)

 

ADRB1

  

0.490

 Arg389Arg, n (%)

756 (50.8)

116 (50.9)

 

 Arg389Gly, n (%)

615 (41.3)

99 (43.4)

 

 Gly389Gly, n (%)

117 (7.9)

13 (5.7)

 

Medication, n (%)

   

 ACE inhibitors

47 (2.4)

30 (11.5)

0.000

 Angiotensin receptor blockers

117 (6.0)

66 (25.4)

0.000

 Beta-blockers

66 (3.4)

87 (33.6)

0.000

 Aldosterone antagonists

3 (0.2)

164 (63.1)

0.000

 Diuretics

17 (0.9)

188 (72.3)

0.000

 Digoxin

3 (0.2)

69 (26.5)

0.000

 Statins

36 (1.8)

127 (48.8)

0.000

 Nitrates

13 (0.7)

145 (55.8)

0.000

  1. Note: BP, blood pressure; LAD, Left atrial diameter; LVEF, left ventricular ejection fraction; LVESD, left ventricular end-systolic dimension; LVEDD, left ventricular end-diastolic dimension; SHF, systolic heart failure.